Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab
Ontology highlight
ABSTRACT: * The recently introduced chemoembolization has been considered to be a very attractive new method in terms of response in the treatment of liver metastases from colon cancer carcinoma (LM-CRC). It appears to be particularly useful if carried out with the new embolization materials.
* An 80% response rate was reported using TACE with Irinotecan pre-loaded Beads in patients with liver metastases from colon cancer, who had been pretreated with 2 or more lines of chemotherapy.
* Since a greater activity was attained by a combination of Cetuximab and Irinotecan versus Cetuximab in monotherapy, the European Agency for the Evaluation of Medicinal Products (EMEA) has granted authorization to the use of Cetuximab in association with irinotecan in the treatment of irinotecan-refractory CRC-LM.
* In this study we want to collect data on on time to progression and tolerability using DEBIRI+Cetuximab in LM-CRC
DISEASE(S): Neoplasm Metastasis,Colon Cancer Liver Metastasis,Liver Neoplasms,Colonic Neoplasms
PROVIDER: 2147713 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA